Categories: Clinical TrialNews

Appiell Announces Strategic Partnership With Symbio Research For SMARTtrial

PLANO, TX / ACCESSWIRE / November 7, 2023 / Appiell, a leading digital AI health company focused on clinical trial software services, and Symbio Research, a client-focused global full-service clinical research organization, have announced a strategic partnership to market and promote Appiell’s multi-faceted digital software platform SMARTtrial. The collaboration aims to accelerate the awareness and use of Appiell’s clinical trial software services, which improve patient compliance and monitoring, streamline process workflows and data collection, and strengthen the quality and compliance of real-time patient reporting while reducing the total time and cost of clinical trial management.

Appiell’s CEO, Scott Jorgensen, expressed his enthusiasm for the partnership, stating “we look forward to launching our partnership with Symbio Research. By leveraging Symbio’s capabilities and relationships, Appiell benefits from accessing a broader commercial network of sponsor companies while furthering its awareness and reach across the clinical development market.”

With the increased use of virtual and de-centralized clinical trial designs and need for more robust patient compliance, monitoring and data collection technologies, Symbio Research, a full-service CRO, identified Appiell as the partner with a highly innovative solution that best suited their clients’ needs. Appiell’s software provides the flexibility to collect patient data, images, and videos via a cloud-based platform through its mobile device application, which allows for a more tailored solution that supports efficient and reliable data collection and sharing remotely. Together, Appiell and Symbio Research will work together to deliver on the promise of faster, more cost-effective and efficient clinical trials.

“We are excited to embark on this commercial partnership with Appiell. We are very impressed with Appiell’s SMARTtrial product and we look forward to offering this new, advanced software platform to our sponsor clients,” said Rich Panico, Co-Founder and CEO of Symbio Research. “As technology becomes more of a focus in clinical trial management, the need for products like these grows.”

About Appiell

Appiell is an emerging digital health company that brings precision and efficiency to the clinical development market by leveraging artificial intelligence, predictive analytics, and advanced data management. By delivering an innovative SaaS solution, Appiell accelerates how clinical trials are enrolled, conducted, and monitored. The Company’s multi-faceted software platform SMARTtrial optimizes process workflows, drives faster patient enrollments, and improves data collection and real-time reporting for clinical trials.

About Symbio Research

Headquartered in Port Jefferson, NY, Symbio Research is a client-focused global full-service clinical research organization that manages all core CRO services including project management, data management, medical monitoring, biostatistics, site selection, compliance, medical writing, and patient recruitment. The company has completed over 200 clinical trials across various stages including expertise in Proof-Of-Concept, medical device, and Phase 1 – 4 clinical studies in the USA and other territories.

For more information, please visit www.appiell.ai and www.symbioresearch.com.

Contact:

Media Relations
info@appiell.ai

SOURCE: Appiell Inc.

View source version on accesswire.com:
https://www.accesswire.com/800346/appiell-announces-strategic-partnership-with-symbio-research-for-smarttrial

Staff

Recent Posts

Masimo Responds to Politan’s Continuing Misrepresentations

IRVINE, Calif.--(BUSINESS WIRE)--To ensure that Politan lies repeated over and over are not taken as…

47 mins ago

Complete Care Lakeview Announces Name Change to Complete Care Wayne Hills Rehab & Respiratory Center

WAYNE, NJ / ACCESSWIRE / July 15, 2024 / Complete Care Lakeview, a leading provider…

51 mins ago

Modular Medical Announces Proof-of-Concept Study for Personalized Metabolic Therapy utilizing the MODD1 Platform

Pre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short…

51 mins ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL…

51 mins ago

Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology

ORLANDO, FL / ACCESSWIRE / July 15, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of…

51 mins ago